GNI Group

2160.TTSE GROWTHPharmaceutical

Filed as GNI Group Ltd. (2022-08–2026-08)

Financials · Consolidated

Fiscal year ended	2025-12	2024-12	2023-12	2022-12	2021-12	2020-12
Revenue	¥26.8bn	¥23.6bn^r	¥26.0bn^r	¥17.4bn^r	¥12.7bn^r	¥9.8bn
Operating income	−¥3.5bn	¥1.4bn^r	¥13.1bn	¥1.4bn	¥1.6bn	—
Net income (owners)	−¥4.2bn	¥1.1bn^r	¥8.1bn^r	¥388m^r	¥1.1bn^r	¥1.3bn
Total assets	¥83.8bn	¥71.9bn^r	¥64.3bn^r	¥33.9bn^r	¥30.3bn^r	¥23.2bn
Net assets / equity	¥51.8bn	¥39.7bn^r	¥36.5bn^r	¥19.8bn	¥19.3bn	¥12.8bn
Operating cash flow	−¥2.4bn	−¥3.2bn^r	¥6.5bn^r	¥393m^r	¥552m^r	¥1.4bn
EPS (basic)	¥-80.9	¥21.96	¥169.5	¥8.19	¥22.72	¥28.96

From EDINET filings. Select any figure to open the report it came from. ^r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 13

All Annual 4 Half-year 3 Quarterly 62026 2025 2024 2023 2022

Period	Form	Filed	Figures
2026-01-01 → 2026-06-30	Half-year	2026-08-14	89 figures · EDINET
2025-01-01 → 2025-12-31	Annual	2026-03-27	209 figures · EDINET
2025-01-01 → 2025-06-30	Half-year	2025-08-14	89 figures · EDINET
2024-01-01 → 2024-12-31	Annual	2025-03-31	209 figures · EDINET
2024-01-01 → 2024-06-30	Half-year	2024-08-14	105 figures · EDINET
2024-01-01 → 2024-03-31	Quarterly Q1	2024-05-15	89 figures · EDINET
2023-01-01 → 2023-12-31	Annual	2024-03-28	207 figures · EDINET
2023-01-01 → 2023-09-30	Quarterly Q3	2023-11-14	111 figures · EDINET
2023-01-01 → 2023-06-30	Quarterly Q2	2023-08-14	111 figures · EDINET
2023-01-01 → 2023-03-31	Quarterly Q1	2023-05-15	89 figures · EDINET
2022-01-01 → 2022-12-31	Annual	2023-03-31	206 figures · EDINET
2022-01-01 → 2022-09-30	Quarterly Q3	2022-11-14	111 figures · EDINET
2022-01-01 → 2022-06-30	Quarterly Q2	2022-08-15	111 figures · EDINET

32 more reports are still being processed.

Segments · FY ended 2025-12

Segment	External sales	Profit
Medical Device	¥7.7bn	¥533m
Pharmaceutical	¥19.2bn	−¥4.0bn
Total	¥26.8bn	−¥3.5bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.